scholarly journals Cervical cancer chemoprevention, vaccines, and surrogate endpoint biomarkers

Cancer ◽  
2003 ◽  
Vol 98 (S9) ◽  
pp. 2044-2051 ◽  
Author(s):  
Michele Follen ◽  
Frank L. Meyskens ◽  
Ronald D. Alvarez ◽  
Joan L. Walker ◽  
Maria C. Bell ◽  
...  
Keyword(s):  
Cervical Cancer ◽  
Cancer Chemoprevention ◽  
Surrogate Endpoint ◽  
Surrogate Endpoint Biomarkers

scholarly journals Surrogate endpoint biomarkers for cervical cancer chemoprevention trials

1995 ◽  
Vol 59 (S23) ◽  
pp. 113-124 ◽  
Author(s):  
Mack T. Ruffin ◽  
Mohammed S. Ogaily ◽  
Carolyn M. Johnston ◽  
Lucie Gregoire ◽  
Wayne D. Lancaster ◽  
...  
Keyword(s):  
Cervical Cancer ◽  
Cancer Chemoprevention ◽  
Surrogate Endpoint ◽  
Surrogate Endpoint Biomarkers

scholarly journals Crinamine Induces Apoptosis and Inhibits Proliferation, Migration, and Angiogenesis in Cervical Cancer SiHa Cells

Biomolecules ◽  
2019 ◽  
Vol 9 (9) ◽  
pp. 494 ◽  
Author(s):  
Khumkhrong ◽  
Piboonprai ◽  
Chaichompoo ◽  
Pimtong ◽  
Khongkow ◽  
...  
Keyword(s):  
Cervical Cancer ◽  
Anticancer Activity ◽  
Cancer Cells ◽  
Mechanism Of Action ◽  
Epithelial Mesenchymal Transition ◽  
Cancer Chemoprevention ◽  
Bioactive Compound ◽  
Perennial Herb ◽  
Mesenchymal Transition ◽  
Cervical Cancer Cells

Crinum asiaticum is a perennial herb widely distributed in many warmer regions, including Thailand, and is well-known for its medicinal and ornamental values. Crinum alkaloids contain numerous compounds, such as crinamine. Even though its mechanism of action is still unknown, crinamine was previously shown to possess anticancer activity. In this study, we demonstrate that crinamine was more cytotoxic to cervical cancer cells than normal cells. It also inhibited anchorage-independent tumor spheroid growth more effectively than existing chemotherapeutic drugs carboplatin and 5-fluorouracil or the CDK9 inhibitor FIT-039. Additionally, unlike cisplatin, crinamine induced apoptosis without promoting DNA double-strand breaks. It suppressed cervical cancer cell migration by inhibiting the expression of positive regulators of epithelial-mesenchymal transition SNAI1 and VIM. Importantly, crinamine also exerted anti-angiogenic activities by inhibiting secretion of VEGF-A protein in cervical cancer cells and blood vessel development in zebrafish embryos. Gene expression analysis revealed that its mechanism of action might be attributed, in part, to downregulation of cancer-related genes, such as AKT1, BCL2L1, CCND1, CDK4, PLK1, and RHOA. Our findings provide a first insight into crinamine's anticancer activity, highlighting its potential use as an alternative bioactive compound for cervical cancer chemoprevention and therapy.

A short-term biomarker modulation prevention study of anastrazole in women at increased risk for breast cancer

2009 ◽  
Vol 27 (15_suppl) ◽  
pp. 1514-1514
Author(s):  
B. Arun ◽  
V. Valero ◽  
A. Brewster ◽  
A. Gutierrez ◽  
M. Green ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Contralateral Breast Cancer ◽  
Surrogate Endpoint ◽  
Phase Iii ◽  
Prevention Study ◽  
Short Term ◽  
Ki 67 ◽  
Increased Risk ◽  
Surrogate Endpoint Biomarkers ◽  
Large Phase

1514 Background: Selective estrogen receptor modulators (SERMs) reduce the risk of breast cancer. Acceptance of SERMs is low due to toxicities. Agents with a better toxicity profile and surrogate endpoint biomarkers to evaluate the effect of preventive agents are needed. In addition to reducing the risk of recurrence of breast cancer, the aromatase inhibitors (AI) have been shown to reduce the risk of contralateral breast cancer in large phase III adjuvant studies. Our objective in this prospective short-term prevention study was to evaluate the effect of anastrozole on surrogate endpoint biomarkers in breast tissue and serum of women with breast cancer who are at increased risk for developing a contralateral second primary breast cancer. Methods: Women with a history of stage I, II breast cancer who were scheduled to start anastrozole for standard adjuvant treatment were eligible. After signing informed consent, patients underwent baseline fine needle aspiration (FNA) of the unaffected breast and serum collection for biomarker analysis before starting anastrozole at 1 mg per oral /day. A repeat FNA and serum collection were performed after 6 months of therapy. Biomarker endpoints included changes in ER and KI-67 expression in breast tissue analyzed by immunohistochemistry and insulin-like growth factor binding protein (IGFBP-1) in serum analyzed by ELISA. The difference in biomarkers before and after treatment was assessed using a Wilcoxon signed-rank test. Results: Forty two patients were enrolled and accrual has been completed. Median age was 58.8 (range 48–75). There was no change in ER or Ki-67 expression in pre- and posttreatment FNA samples. However, there was a statistically significant difference in pre- and posttreatment serum IGFBP-1 levels (p = 0.014); with pre-and post- mean treatment levels being 9.2 ng/mL and 13.5 ng/mL, respectively. Conclusions: We found a significant modulation of IGFBP-1 levels with 6 months of anastrozole treatment in women at increased risk of developing contralateral breast cancer. Anastrozole is currently being studied as a prevention agent in a large phase III trial, and our results provide support for continued evaluation of IGFBP-1 as a surrogate endpoint biomarker in prospective breast chemoprevention studies. [Table: see text]

scholarly journals Overview of Biomarkers and Surrogate Endpoints in Drug Development

2002 ◽  
Vol 18 (2) ◽  
pp. 41-46 ◽  
Author(s):  
John A. Wagner
Keyword(s):  
Drug Development ◽  
Expression Profiling ◽  
Biomarker Discovery ◽  
Surrogate Endpoint ◽  
Peroxisome Proliferator ◽  
Complement Protein ◽  
High Quality Research ◽  
Surrogate Endpoint Biomarkers ◽  
Peroxisome Proliferator Activated Receptors

There are numerous factors that recommend the use of biomarkers in drug development including the ability to provide a rational basis for selection of lead compounds, as an aid in determining or refining mechanism of action or pathophysiology, and the ability to work towards qualification and use of a biomarker as a surrogate endpoint. Examples of biomarkers come from many different means of clinical and laboratory measurement. Total cholesterol is an example of a clinically useful biomarker that was successfully qualified for use as a surrogate endpoint. Biomarkers require validation in most circumstances. Validation of biomarker assays is a necessary component to delivery of high-quality research data necessary for effective use of biomarkers. Qualification is necessary for use of a biomarker as a surrogate endpoint. Putative biomarkers are typically identified because of a relationship to known or hypothetical steps in a pathophysiologic cascade. Biomarker discovery can also be effected by expression profiling experiment using a variety of array technologies and related methods. For example, expression profiling experiments enabled the discovery of adipocyte related complement protein of 30 kD (Acrp30 or adiponectin) as a biomarker forin vivoactivation of peroxisome proliferator-activated receptors (PPAR)γactivity.

Surrogate endpoint biomarkers for human colon carcinogenesis

2000 ◽  
Vol 112-113 ◽  
pp. 415-420 ◽  
Author(s):  
Piero Dolara ◽  
Giovanna Caderni ◽  
Cristina Luceri
Keyword(s):  
Colon Carcinogenesis ◽  
Surrogate Endpoint ◽  
Human Colon ◽  
Surrogate Endpoint Biomarkers
Sign in / Sign up

Export Citation Format

Share Document